Experimental evidence search

The in vitro HIV-1 infection model revealed 2.5-fold lower mean IC50 for bio-synthetic modified enfuvirtide 0.0453 μM [95% CI 0.0316–0.0650].

the standard had 0.0180 μM [95% CI 0.0090–0.0359].

RV-23 was found to be more active than AR-23, with an inhibitory concentration of 50% (IC50) at 10 μM ... in co-treatment.

RV-23 was found to be more active than AR-23, with an inhibitory concentration of 50% (IC50) at ... 12.5 μM in co-treatment.

RV-23 ... IC50 at ... 6.25 μM ... in virus pre-treatment assays.

AR-23 was characterized by an IC50 at 10 μM in the same treatment (virus pre-treatment).

On the contrary, no activity was observed after the viral adsorption step (post-treatment), indicating that the peptides did not interfere later in the infection.

On the contrary, no activity was observed after the viral adsorption step (post-treatment), indicating that the peptides did not interfere later in the infection.

Using the data obtained from RV-23 and AR-23 scramble peptides (Figure 2B,D), we can hypothesize that the antiviral activity ... was strongly associated with the peptide primary sequence. Figure 2B shows no significant inhibition by RV-23 scramble.

Using the data obtained from RV-23 and AR-23 scramble peptides (Figure 2B,D), we can hypothesize that the antiviral activity ... was strongly associated with the peptide primary sequence. Figure 2D shows no significant inhibition by AR-23 scramble.

Table 1: G54-LDL EC50/IC50 <0.5 µM (EMSA).

Table 1: A45-LDL EC50/IC50 0.6 ± 0.1 µM (EMSA).

Table 1: G54-LNA EC50/IC50 <0.5 µM (EMSA).

Table 1: G54-LNA EC50/IC50 26 ± 9 nM (DLA).

Table 1: A45-LNA EC50/IC50 0.3 ± 0.1 µM (EMSA).

Table 1: CPS-1 EC50/IC50 >5 µM (EMSA).

Table 1: CPS-2 EC50/IC50 >5 µM (EMSA).

Table 1: CPS-3 EC50/IC50 2.3 ± 0.4 µM (EMSA).

Table 1: CPS-4 EC50/IC50 >5 µM (EMSA).

Table 1: CPS-5 EC50/IC50 >5 µM (EMSA).